Replies to post #37825 on RespireRx Pharmaceuticals Inc (fka RSPI)

[ombowstring]

<<<Ombow, Samyang would have to run many clinical trials in Asia, in a similar process to what happens for US and European regulatory approval.>>> Do you know that for a fact? How soon might they bring product to market?

<<<But if Samyang can run their own trials using Cortex's two lead compounds, unfortunately that would greatly diminish Cortex's ability to partner those 2 compounds to other Pharmas for other territories and indications. Perhaps Neuro will chime in on the topic if he's out there.>>> I disagree. Cortex is trying to make a move for Asian markets. All other markets are still in their quiver. Everything is the same as it was yesterday re all other markets.

[neuroinv]

Asian markets are a world unto themselves. For example, Lundbeck's Lexapro, which is about to go off-patent next year in the US, was just approved for the first time in Japan earlier this year. These countries require trials with their own populations, and larger companies often outlicense those rights and headaches. Cortex and Samyang appear to have agreed that Samyang will (my guess, I haven't seen the MOU, obviously) have some priority in negotiations for these compounds, and would have a shot at widening their Asian territory. But there is no money changing hands on this, and no binding commitment on either side, so far as I can tell.

Anyways--this expression of interest vis-a-vis these Asian territories should not have any negative effect on any future negotiations for North America/Europe. The full range of clinical studies will be required in Asia, and there is a huge gap between this MOU and the start of any such testing. I don't think Samyang's expression of interest is going to have any impact on large companies--but it is a reminder to Servier that they do not necessarily have a monopoly on the Ampakine franchise. Which is a good thing.

Re: Neurolixis
Mark Varney and Newman-Tancredi are longtime friends, and Varney is providing very limited assistance to N-T in setting up this company. It has nothing to do with Ampakines, there is no transfer of IP or management, and hardly any time. It's not material to Cortex.

NeuroInvestment